From Awareness to Action on Global Fatty Liver Day

Global Liver Institute Unites the Field in Times of Name Changes and New Treatments

WASHINGTON, June 13, 2024 (GLOBE NEWSWIRE) — Today marks the seventh annual Global Fatty Liver Day (formerly International NASH Day), led by Global Liver Institute (GLI) with the theme “Act Now, Screen Today.” This campaign underscores the crucial need for early identification and treatment of fatty liver disease to prevent its progression to chronic liver disease, cirrhosis, or cancer.

Fatty liver disease is now estimated to affect 1 in 3 adults worldwide, and its prevalence is increasing. Fatty liver disease during childhood, once unheard of, is also on the rise. Early detection and timely intervention, whether through lifestyle changes or medical treatments, are essential in stopping and even reversing the progression of the disease. “Act Now, Screen Today” emphasizes that liver health is achievable, but action must begin immediately. Across the globe, partners are driving awareness and educational efforts and ensuring broader access to essential screenings and care.

Global Fatty Liver Day, observed annually on the second Thursday of June, is a rallying cry for collective action to address the growing prevalence of fatty liver disease, the most common liver disease worldwide. “Act Now, Screen Today” reminds everyone that liver health is within reach. Here are specific actions you can take today:

  • Take advantage of liver health screening events happening globally to get assessed for fatty liver disease or schedule a check-up with your doctor, especially if you are managing closely associated metabolic conditions like obesity or diabetes
  • Increase physical activity, as maintaining an active lifestyle can improve liver health
  • Learn about fatty liver disease and its risk factors to take proactive steps towards prevention and management yourself or learn more about the latest research and guidelines for your patients.

With a robust pipeline of pharmaceutical treatments that address diverse mechanisms of action in progress, it is important to identify individuals’ position within the progression of fatty liver disease so that they are poised to receive the most appropriate care possible. Notably, pharmaceutical treatments are available (for certain groups with advanced disease) in two countries, the United States (resmetirom) and India (saroglitazar).

“As a community, we stand at a critical time for the broader global health system to act now to support patients,” shares Donna R. Cryer, JD, Founder and CEO of GLI. “As pharmaceutical treatment options gain approval in different geographies, health payers and systems must listen to the call from global advocates and not place undue obstacles to care – whether that be required biopsy, ambiguous lifestyle requirements, or other hurdles – so that patients are able to access the care they require, no matter who or where they are.”

Recognizing the importance of early detection, a diverse range of partners, including healthcare providers, patient advocacy groups, and community organizations, have joined forces to “Act Now, Screen Today” and launch screening events around the world. From Chile to Nigeria to the Netherlands, the Philippines, and beyond, these events aim to raise awareness, provide education, and offer screening services to individuals at risk of fatty liver disease or the providers who care for them. Global Fatty Liver Day activities are driving positive change at the grassroots level.

“Global Fatty Liver Day is an urgent call-to-action to unite our global efforts to confront the scourge of fatty liver disease,” shares Cat Evans, Director of Program Operations at GLI. “We must act now. By working together, we have the power to create significant change in preventing and managing this pressing health issue through our collaborative efforts.”

Although the challenge of fatty liver disease to the well-being of communities around the globe is great, the power of locally-rooted, collective efforts can turn the tide towards positive change by heightening awareness, equipping people and their healthcare providers with prevention and management tools, expanding understanding of the disease through research, and protecting future liver health through effective policies.

About Global Liver Institute

Global Liver Institute (GLI) is a 501(c)3 nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease. Follow GLI on FacebookInstagramLinkedIn, and YouTube, or visit www.globalliver.org. GLI is the host of Global Fatty Liver Day.

Christine Maalouf
Global Liver Institute
cmaalouf@globalliver.org

GlobeNewswire Distribution ID 9153607

Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen

ADALVO LIMITED
Anil Okay, Adalvo CEO, expresses his thoughts on this milestone

SAN ĠWANN, Malta, June 13, 2024 (GLOBE NEWSWIRE) — Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.

As a bioequivalent version of Victoza® pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug achieved global sales exceeding $4.8 billion in 2023, as reported by IQVIA.

The successful development of Liraglutide highlights Adalvo’s capability to offer a diverse and comprehensive diabetes portfolio, encompassing both complex peptide injectables and small molecule oral treatments.

Adalvo’s commitment to providing access to high-quality differentiated products while simultaneously navigating manufacturing complexities reinforces Adalvo’s position as a trusted leader in the pharmaceutical industry.

Click Here To View Adalvo’s Diabetes Portfolio

At Adalvo, there are no half-measures – they are always on target. Their mission is to be faster and stronger than their competitors, driving their vision forward with a winning team.

Adalvo is committed to maintaining the highest standards of excellence in all their endeavors and looks forward to continuing to deliver innovative healthcare solutions that make a difference in the lives of patients worldwide.

About Adalvo

Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.

Adalvo takes pride in their ability to help partners reach their goals – be those increasing revenues or pushing into new markets. Tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.

The company’s purpose-driven culture is committed to improving the lives of patients around the world. Adalvo’s dynamic leadership team brings significant experience and industry know-how, which has helped to establish the company as a reliable global partner in the industry.

Contacts: Gabrielle Cassar, gabrielle.cassar@adalvo.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e1e895aa-f689-4215-a1f8-25285851af9d

GlobeNewswire Distribution ID 1000966220

Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen

ADALVO LIMITED
Anil Okay, Adalvo CEO, expresses his thoughts on this milestone

SAN ĠWANN, Malta, June 13, 2024 (GLOBE NEWSWIRE) — Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.

As a bioequivalent version of Victoza® pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug achieved global sales exceeding $4.8 billion in 2023, as reported by IQVIA.

The successful development of Liraglutide highlights Adalvo’s capability to offer a diverse and comprehensive diabetes portfolio, encompassing both complex peptide injectables and small molecule oral treatments.

Adalvo’s commitment to providing access to high-quality differentiated products while simultaneously navigating manufacturing complexities reinforces Adalvo’s position as a trusted leader in the pharmaceutical industry.

Click Here To View Adalvo’s Diabetes Portfolio

At Adalvo, there are no half-measures – they are always on target. Their mission is to be faster and stronger than their competitors, driving their vision forward with a winning team.

Adalvo is committed to maintaining the highest standards of excellence in all their endeavors and looks forward to continuing to deliver innovative healthcare solutions that make a difference in the lives of patients worldwide.

About Adalvo

Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.

Adalvo takes pride in their ability to help partners reach their goals – be those increasing revenues or pushing into new markets. Tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.

The company’s purpose-driven culture is committed to improving the lives of patients around the world. Adalvo’s dynamic leadership team brings significant experience and industry know-how, which has helped to establish the company as a reliable global partner in the industry.

Contacts: Gabrielle Cassar, gabrielle.cassar@adalvo.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e1e895aa-f689-4215-a1f8-25285851af9d

GlobeNewswire Distribution ID 1000966220

Nikkiso Clean Energy & Industrial Gases Group Announces CEO Transition July 1, 2024

TEMECULA, Calif., June 13, 2024 (GLOBE NEWSWIRE) — Nikkiso Co., Ltd. (TSE: 6376), announced today after a Board vote, that effective July 1, 2024, Adrian Ridge will succeed Peter Wagner as Nikkiso Clean Energy & Industrial Gases Group’s (part of Nikkiso’s Industrial Division) as Chief Executive Officer. Wagner will stay on in a Board role as Executive Chairman for Nikkiso CE&IG Group.

As CEO, Ridge, who is currently Executive Vice President, Operations and Manufacturing for Nikkiso CE&IG Group, will drive operational and financial results and ready the Group for future growth. Wagner’s new role as Executive Chairman will focus on driving the vision and long-term strategy of the Group in an advisor capacity.

“In six years under Peter’s leadership, Nikkiso CE&IG has more than quadrupled business, and is positioned for strong continued growth,” said Toshihiko Kai, President and CEO, Nikkiso. “I want to thank him for his leadership, and welcome Adrian as the Group’s new CEO.”

Prior to joining Nikkiso in 2018, Wagner was CEO and Managing Director at LEWA Group. Ridge joined Nikkiso in 2022 after approximately 30 years at Atlas Copco serving in various leadership positions.

About Nikkiso Co. Ltd.

Since its establishment in 1953, Nikkiso has contributed to solving social issues by anticipating the changing times with world-first and Japan-first technologies and products. In the industrial business, Nikkiso has created new markets by developing products in the energy field, hemodialysis-related products in the medical business, and CFRP (carbon fiber reinforced plastic) aerostructures in the aerospace business.

About Nikkiso Clean Energy & Industrial Gases Group

The Nikkiso Clean Energy & Industrial Gases Group is a leading provider of cryogenic equipment, technologies and applications for clean energy and industrial gas market segments. The Group employs more than 1,600 people in 22 countries and is headed by Cryogenic Industries, Inc. in Southern California, U.S., which is a wholly owned subsidiary of Nikkiso Co., Ltd. (TSE: 6376).

Media contact
Lisa Adams
+1 405 492 1689

GlobeNewswire Distribution ID 9153273

‫منصة إكس ترانسفير وبنك بانكنج سيركل يعلنان شراكة استراتيجية

شراكة من المقرر أن تعزز إمكانيات الدفع للواردات/الصادرات في أوروبا والشرق الأوسط

المنطقة الإدارية الخاصة في هونغ كونغ، 11 يونيو 2024 – ثمة شراكة استراتيجية قد عُقدت بين منصة إكس ترانسفير، المنصة الأولى في الصين والرائدة على مستوى العالم لمدفوعات التجارة العابرة للحدود بين الشركات؛ وبنك بانكنج سيركل، بنك المدفوعات المبنية على التكنولوجيا المبتكرة. ويهدف هذا التعاون إلى تقليل تكلفة ووقت معالجة المدفوعات العابرة للحدود لصالح عملاء إكس ترانسفير، وخصوصًا إفادة الموردين الصينيين من الأسواق الكبيرة في أوروبا والشرق الأوسط.

يُعد كل من منصة إكس ترانسفير وبنك بانكنج سيركل ملتزمان بتقليل التكلفة المرتبطة بمدفوعات التجارة العالمية. وتركز إكس ترانسفير على تزويد الشركات الصغيرة والمتوسطة بحلول دفع وتحصيل أموال عابرة للحدود ومعقولة التكلفة وسريعة ومتوافقة وآمنة، مما يعزز من التنافس العالمي ويسهل التوسع الدولي. أنشأ بنك بانكنج سيركل شبكة مقاصة محلية شاملة للعملات الرئيسية ومحرك عملات أجنبية فعال يدعم 24 عملة، مما يوفر مدفوعات سريعة وقليلة التكلفة دون رسوم مخفية.

ومن خلال تكامل البنية الأساسية لبنك بانكنج سيركل، تستطيع إكس ترانسفير الآن أن تقدم لعملائها مجموعة واسعة من خيارات الدفع وتحصيل الأموال المحلية. وسيكون العملاء قادرين على تلقي المدفوعات ليس فقط بالعملات الرئيسية مثل الدولار الأمريكي واليورو والجنيه الاسترليني والكرونة الدنماركية، ولكن أيضًا بست عملات إضافية في أوروبا والشرق الأوسط. ومن المتوقع أن تتوسع هذه الشراكة بشكل أكبر، مع وجود خطط لتقديم المزيد من خيارات العملات في المستقبل القريب.

وهذا التطور مفيد بشكل خاص للشركات التي تتعامل مع الموردين الصينيين. وسيتمتع المشترون في أوروبا والشرق الأوسط بسهولة الدفع للموردين الصينيين بمجموعة واسعة من العملات المحلية.

وتعليقًا على الشراكة؛ صرح بيل دينج، المؤسس والرئيس التنفيذي لشركة إكس ترانسفير، قائلاً: “يمثل تعاوننا مع بنك بانكنج سيركل خطوة مهمة نحو الأمام في طريقنا للتوسع في الأسواق الأوروبية والشرق أوسطية. ولا يقتصر دور هذه الشراكة على تسريع الطموحات العالمية لشركة إكس ترانسفير فحسب، بل تقدم وعدًا أيضًا بإحداث ثورة في مشهد التجارة الدولية للشركات. ونحرص دائمًا على رؤية النجاح المستمر لهذا التعاون.”

أضاف لاوست بيرتيلسن، المؤسس المشارك والرئيس التنفيذي لبنك بانكنج سيركل، قائلاً: “يسعدنا دعم رؤية إكس ترانسفير للتجارة العالمية. ومن خلال الاستفادة من حسابات بانكنج سيركل وأنظمة الدفع، يمكن لشركة إكس ترانسفير تبسيط عملية الدفع لعملائها، مما يقلل من التكاليف ومن أوقات المعاملات.”

إكس ترانسفير

إكس ترانسفير، منصة الدفع للتجارة العابرة للحدود بين الشركات والتي تشغل المرتبة الأولى في الصين، مكرسة لتزويد الشركات الصغيرة والمتوسطة بحلول دفع وتحصيل أموال للتجارة الخارجية، والتي تكون آمنة ومتوافقة وسريعة ومريحة ومنخفضة التكلفة، مما يقلل بشكل كبير من تكلفة التوسع العالمي ويعزز التنافسية العالمية. وقد تأسست الشركة في عام 2017، ويقع المقر الرئيسي للشركة في شنغهاي، ولها فروع في هونغ كونغ والمملكة المتحدة وهولندا والولايات المتحدة وكندا واليابان وأستراليا وسنغافورة. حصلت إكس ترانسفير على تراخيص للمدفوعات المحلية في هونغ كونغ والمملكة المتحدة والولايات المتحدة وكندا وأستراليا. وأصبحت إكس ترانسفير الصناعة رقم 1 في الصين بما لديها من أكثر من 450,000 عميل من عملاء المؤسسات.

من خلال التعاون مع البنوك والمؤسسات المالية متعددة الجنسيات المعروفة، قامت إكس ترانسفير ببناء شبكة مقاصة عالمية موحدة متعددة العملات وأنشأت بنية أساسية ذكية ومؤتمتة ومعتمدة على البيانات ومعتمدة على الإنترنت ومكافحة لمخاطر غسيل الأموال تتمحور حول المؤسسات الصغيرة والمتوسطة. تستخدم إكس ترانسفير التكنولوجيا كجسر لربط المؤسسات المالية الكبيرة والمؤسسات الصغيرة والمتوسطة حول العالم، مما يسمح للشركات الصغيرة والمتوسطة بالاستمتاع بنفس مستوى الخدمات المالية العابرة الحدود مثل الشركات الكبيرة متعددة الجنسيات.

أكملت إكس ترانسفير تمويلها من السلسلة “د” في سبتمبر 2021، وحققت مكانة وحيد القرن. تمتلك الشركة تشكيلة متنوعة من المستثمرين الدوليين، بما في ذلك D1 Capital Partners LP، وTelstra Ventures، وChina Merchants Venture، وeWTP Capital، وYunqi Capital، وGaorong Capital، و01VC، وMindWorks، وLavender Hill Capital Partners.

لمزيد من المعلومات: https://www.xtransfer.com/

 بانكنج سيركل ش.م

بانكنج سيركل هو بنك المدفوعات للاقتصاد الجديد. وباعتباره بنكًا مرخصًا بالكامل وخاليًا من الأنظمة القديمة، فإن بنك بانكنج سيركل يُمكّن شركات المدفوعات والبنوك من أي حجم من اغتنام الفرص في الاقتصاد الجديد – وذلك بوتيرة سريعة وبتكلفة منخفضة.

بانكنج سيركل ش.م هو بنك متوافق وحديث ملتزم ببناء شبكة مقاصة محلية لجميع العملات الرئيسية، لتقديم مدفوعات سريعة ومنخفضة التكلفة دون أي رسوم خفية للمستفيد. وهو يوفر مجموعة من الحلول المصرفية الفريدة والحائزة على جوائز، بما في ذلك الحسابات المصرفية متعددة العملات، وأرقام الآيبان الافتراضية، والاتصالات المصرفية للمقاصة المحلية، والمدفوعات عبر الحدود، وكلها مدعومة بالامتثال والأمن الرائدين في السوق.

من خلال حلول مخصصة ومرنة وقابلة للتطوير ومواكبة للمستقبل، يعمل بانكنج سيركل ش.م على تمكين المؤسسات المالية من مساعدة عملائها على إجراء المعاملات عبر الحدود بطريقة لم تكن ممكنة في السابق.

يقع المقر الرئيسي لبنك بانكنج سيركل في لوكسمبورغ، وله مكاتب في لندن وميونيخ وكوبنهاغن.

XTransfer and Banking Circle Announce Strategic Partnership

Collaboration Set to Boost Payment Capabilities for Importers/Exporters  in Europe and the Middle East

HONG KONG SAR – Media OutReach Newswire – 11 June 2024 – XTransfer, the World’s Leading & China’s No.1 B2B Cross-Border Trade Payment Platform, and Banking Circle, the innovative tech-driven Payments Bank, have entered into a strategic partnership. This collaboration aims to reduce the cost and processing time of cross-border payments for XTransfer’s clients, particularly benefiting Chinese suppliers with significant markets in Europe and the Middle East.

Both XTransfer and Banking Circle are committed to minimising the cost associated with global trade payments. XTransfer focuses on providing SMEs with secure, compliant, fast, and cost-effective cross-border payment and fund collection solutions, thereby enhancing global competitiveness and facilitating international expansion. Banking Circle has established a comprehensive local clearing network for major currencies and an effective FX engine supporting 24 currencies, ensuring quick, low-cost payments without hidden fees.

Through the integration of Banking Circle’s infrastructure, XTransfer can now offer its clients a broader array of local payment and fund collection options. Clients will be able to receive payments not only in major currencies like the US Dollar, Euro, GBP, and Danish Krone, but also in six additional currencies in Europe and the Middle East. This partnership is expected to expand further, with plans to introduce even more currency options in the near future.

This development is particularly advantageous for businesses dealing with Chinese suppliers. Buyers in Europe and the Middle East will have the convenience of paying Chinese suppliers in a wider range of local currencies.

Bill Deng, Founder and CEO of XTransfer, commented on the partnership, “Our alliance with Banking Circle represents a significant step forward in our expansion into the European and Middle Eastern markets. This partnership not only accelerates XTransfer’s global ambitions but also promises to revolutionise the international trade landscape for businesses. We are eager to see the continued success of this collaboration.”

Laust Bertelsen, Co-Founder and CEO of Banking Circle added, “We are thrilled to support XTransfer’s vision for global trade. By leveraging Banking Circle’s accounts and payment rails, XTransfer can streamline the payment process for its clients, reducing both costs and transaction times.”

XTransfer

XTransfer, World’s Leading & China’s No.1 B2B Cross-Border Trade Payment Platform, is dedicated to providing SMEs with secure, compliant, fast, convenient and low-cost foreign trade payment & fund collection solutions, significantly reducing the cost of global expansion and enhancing global competitiveness. Founded in 2017, the company is headquartered in Shanghai and has branches in Hong Kong, the United Kingdom, the Netherlands, the United States, Canada, Japan, Australia, and Singapore. XTransfer has obtained local payment licenses in Hong Kong, the United Kingdom, the United States, Canada, and Australia. With more than 450,000 enterprise clients, XTransfer has become the industry No.1 in China.

By cooperating with well-known multinational banks and financial institutions, XTransfer has built a unified global multi-currency clearing network and built a data-based, automated, Internet-based and intelligent anti-money laundering risk control infrastructure centred on small and medium enterprises. XTransfer uses technology as a bridge to link large financial institutions and small and medium enterprises around the world, allowing SMEs to enjoy the same level of cross-border financial services as large multinational corporations.

XTransfer completed its Series D financing in September 2021 and achieved unicorn status. The Company possesses a diverse composition of international investors, including D1 Capital Partners LP, Telstra Ventures, China Merchants Venture, eWTP Capital, Yunqi Capital, Gaorong Capital, 01VC, MindWorks and Lavender Hill Capital Partners.

For more information: https://www.xtransfer.com/